An interventional study of Riboflavin and Folic acid in Blood Pressure, sponsored by University of Ulster. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-18.
Sponsored by University of Ulster · Not applicable, Interventional, and Prevention
Approximately 12% of the world's population have a have a common C677T polymorphism in the gene encoding the folate metabolising enzyme, methylenetetrahydrofolate reductase (MTHFR). Homozygosity for the polymorphism (TT genotype) causes an increased requirement for the B-vitamins folic acid and riboflavin and more importantly results in an increased risk of developing high blood pressure (BP). Previous work from our Centre has demonstrated significantly higher BP in those with the TT genotype. This work has been conducted in cohorts with premature cardiovascular disease (CVD) and hypertension without overt CVD, but the effect in younger, healthier individuals is unexplored. To date our studies have also focused on BP as the primary outcome, but newer markers of vascular health including central pressure and hemodynamics have emerged as superior prognostic indicators of CVD. The effect of the TT genotype on these measures is an area for investigation and may help us understand the mechanism linking the genotype with BP, which is currently unknown. As adults with the TT genotype have increased requirements for riboflavin and folic acid, and BP in TT adults appears to be riboflavin dependent, the influence of these vitamins on central measures is an area for consideration. Study Design This is an observational study investigating the blood pressure profiles of healthy adults aged 18-65 years, stratified by MTHFR genotype. Apparently healthy adults will be recruited from workplaces and the general community across Northern Ireland and screened for the polymorphism via buccal swab. Those with the TT genotype and a similar number of non-TT (i.e. CC/CT) genotype individuals will be contacted and asked to come to a one-off appointment. Brachial BP will be assessed by an electronic BP monitor, central BP and central haemodynamics (augmentation index, augmentation pressure and pulse wave velocity) will be assessed by SphygmoCor XCEL. In addition, anthropometric measurements, health and lifestyle infromation and a blood sample will be obtained. Data will be statistically analysed using SPSS software to if determine differences between gentoype groups exist.
6,687 studies on the registry are indexed under Hypertension; 964 are open to participants now.
This study's enrollment of 2,564 is above the median of 90 across 4,994 interventional studies indexed under Hypertension.
Browse Hypertension studies →University of Ulster is the lead sponsor of 94 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
1.6 mg riboflavin / day for 24 weeks
Dietary Supplement: Riboflavin
0.4 mg folic acid/ day for 24 weeks
Dietary Supplement: Folic acid
1.6mg Riboflavin + 0.4 mg Folic Acid / day for 24 weeks
Dietary Supplement: Riboflavin · Dietary Supplement: Folic acid
Dietary Supplement: Placebo
1.6 mg riboflavin / day for 24 weeks
0.4 mg folic acid / day for 24 weeks
Blood pressure
Office blood pressure
Time frame: Change from baseline to 24 weeks
Central blood pressure
Measured using SphygmoCor device
Time frame: Change from baseline to 24 weeks
Pulse wave analysis
Measured using SphygmoCor device
Time frame: Change from baseline to 24 weeks
Pulse wave velocity
Measured using SphygmoCor device
Time frame: Change from baseline to 24 weeks
Red blood cell riboflavin
Measured using erythrocyte glutathione reductase activity coefficient (EGRAC)
Time frame: Change from baseline to 24 weeks
Red blood cell folate
Measured by microbiological assay
Time frame: Change from baseline to 24 weeks
Serum homocysteine
Measured using an immunoassay
Time frame: Change from baseline to 24 weeks
Plasma vitamin B6
Measured by High Performance Liquid Chromatography
Time frame: Change from baseline to 24 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Ulster